Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents

Epidemiology and Infection

Volumn 139, Issue 9, 2011, Pages 1342-1350

  McKinnell, J A ^a,b   Patel, M ^c,d   Shirley, R M ^c   Kunz, D F ^e   Moser, S A ^f   Baddley, J W ^c,d  

^a UCLA MEDICAL CENTER   (United States)

^b TORRANCE MEMORIAL MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

Antibiotic resistance; antibiotics; Enterococcus; hospital acquired (nosocomial) infections

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; IMMUNOSUPPRESSIVE AGENT; LINEZOLID;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCAL INFECTION; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL RATE; TERTIARY HEALTH CARE; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AGED; ANTI-INFECTIVE AGENTS; BACTEREMIA; DAPTOMYCIN; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; VANCOMYCIN RESISTANCE;

EID: 80053115233     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810002475     Document Type: Article

References (33)

1. Hidron AI, et al. NHSN annual update: antimicrobialresistant pathogens associated with healthcareassociated infections : annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infection Control and Hospital Epidemiology 2008; 29: 996-1011
2. Deshpande LM, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Diseases 2007; 58: 163-170 (Pubitemid 46856806)
3. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary fromJanuary 1992 through June 2004, issued October 2004 American Journal of Infection Control 2004; 32: 470-485
4. Vergis EN, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Annals of Internal Medicine 2001; 135: 484-492 (Pubitemid 32923565)
5. Erlandson KM, et al. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clinical Infectious Diseases 2008; 46: 30-36 (Pubitemid 351263556)
6. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. Journal of Infectious Diseases 2005; 191: 588-595 (Pubitemid 40216675)
7. Gearhart M, et al. Consequences of vancomycinresistant Enterococcus in liver transplant recipients : a matched control study. Clinical Transplantation 2005; 19: 711-716 (Pubitemid 41748721)
8. Garbutt JM, et al. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clinical Infectious Diseases 2000; 30: 466-472 (Pubitemid 30205290)
9. Song JH, et al. Clinical implications of vancomycinresistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. Journal of Antimicrobial Chemotherapy 2008; 61: 838-844
10. Song X, et al. Effect of nosocomial vancomycinresistant enterococcal bacteremia on mortality, length of stay, and costs. Infection Control and Hospital Epidemiology 2003; 24: 251-256 (Pubitemid 36538136)
11. Papanicolaou GA, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients : risk factors for acquisition and mortality. Clinical Infectious Diseases 1996; 23: 760-766
12. DiazGranados CA, et al. Comparison of mortality associated with vancomycin-resistant and vancomycinsusceptible enterococcal bloodstream infections : a meta-analysis. Clinical Infectious Diseases 2005; 41: 327-333 (Pubitemid 41022109)
13. Warren RE. Daptomycin in endocarditis and bacteraemia: a British perspective. Journal of Antimicrobial Chemotherapy 2008; 62 (Suppl. 3) : 25-33
14. Schwartz BS, Ngo PD, Guglielmo BJ. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis : impact of protein binding? Annals of Pharmacotherapy 2008; 42: 289-290 (Pubitemid 351238581)
15. Mohr JF, et al. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). International Journal of Antimicrobial Agents 2009; 33: 543-548
16. Mave V, et al. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid ? Journal of Antimicrobial Chemotherapy 2009; 64: 175-180
17. Camins BC, et al. A population-based investigation of invasive vancomycin-resistant Enterococcus infection in metropolitan Atlanta, Georgia, and predictors of mortality. Infection Control and Hospital Epidemiology 2007; 28: 983-991 (Pubitemid 47218280)
18. Bhavnani SM, et al. A nationwide, multicenter, casecontrol study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagnostic Microbiology and Infectious Diseases 2000; 36: 145-158 (Pubitemid 30145652)
19. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infectionand criteria for specific types of infections in the acute care setting. American Journal of Infection Control 2008; 36: 309-332 (Pubitemid 351763841)
20. Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies : development and validation. Journal of Chronic Diseases 1987; 40: 373-383 (Pubitemid 17055592)
21. Boucher HW, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 2009; 48: 1-12
22. Reik R, et al. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004 Diagnostic Microbiology and Infectious Diseases 2008; 62: 81-85
23. Ghanem G, et al. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infection Control and Hospital Epidemiology 2007; 28: 1054-1059 (Pubitemid 47345265)
24. Poutsiaka DD, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Journal of Infection 2007; 54: 567-571 (Pubitemid 46731225)
25. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis : a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-332
26. Raad, II, et al. Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrobial Agents and Chemotherapy 2005; 49: 5046-5050 (Pubitemid 41778919)
27. Moellering RC, et al. The efficacy and safety of quinupristin/ dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. Journal of Antimicrobial Chemotherapy 1999; 44: 251-261 (Pubitemid 29389289)
28. Kvirikadze N, et al. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scandinavian Journal of Infectious Diseases 2006; 38: 290-292 (Pubitemid 43832417)
29. Cunha BA, Mickail N, Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart and Lung 2007; 36: 456-461 (Pubitemid 350086682)
30. Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. Journal of Antimicrobial Chemotherapy 2008; 62 (Suppl. 3) : 35-39
31. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical Infectious Diseases 2000; 30: 146-151 (Pubitemid 30067072)
32. Fowler Jr. VG, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists : experience with 244 patients. Clinical Infectious Diseases 1998; 27: 478-486 (Pubitemid 28421994)
33. Patel M, et al. Initial management of candidemia at an academic medical center : evaluation of the IDSA guidelines. Diagnostic Microbiology and Infectious Diseases 2005; 52: 29-34 (Pubitemid 40692736)